NEW YORK ( TheStreet) -- CHANGE IN RATINGS Advanced Micro Devices ( AMD) upgraded at Jefferies to Buy from Hold, Jefferies said. $10.50 price target. One of best risk reward ratios in semis. AthenaHealth ( ATHN) downgraded at Auriga from Hold to Sell, Auriga USA said. Valuation call, based on a $57 price target. BioLase Technology ( BLTI) downgraded to sell at TheStreet Ratings. Digital Realty Trust ( DLR) downgraded at Jefferies to Hold from Buy, Jefferies said. $73 price target. Valuation finally catching up with the story. eBay ( EBAY) downgraded at Credit Suisse from Outperform to Neutral, Credit Suisse said. Valuation call, based on a $40 price target. Joy Global ( JOY) downgraded at UBS to Neutral from Buy, UBS said. $85 price target. Cheap natural gas is leading US utilities to switch from coal. Lazard ( LAZ) downgraded at BofA/Merrill from Neutral to Underperform, Bank of America/Merrill Lynch said. $26 price target. Estimates also cut, because of higher compensation rates. Level 3 Communications ( LVLT) upgraded at BofA/Merrill to Buy, Bank of America/Merrill Lynch said. Risk/reward is attractive at current levels. $37.50 price target. Majesco Entertainment ( COOL) upgraded to buy at TheStreet Ratings. Progress Energy ( PGN) rated new Hold at Dahlman. Company is leveraged to long-dated gas production, but has near-term cash flow risks. Stryker ( SYK) rated new Outperform at Credit Suisse. $63 price target. Volumes should recover without the need for lower pricing. Veeco Instruments ( VECO) upgraded at Deutsche from Hold to Buy, Deutsche Bank said. $40 price target. Checks suggest that fundamentals are improving for MOCVD suppliers. WMS Industries ( WMS) downgraded at Goldman from Neutral to Sell, Goldman Sachs said. $19 price target. Recent survey suggests that a potential recovery could take longer to materialize. Exco Resources ( XCO) downgraded at Jefferies to Underperform from Hold, Jefferies said. $4 price target. Natural gas leverage is painful. Zimmer ( ZMH) rated new Outperform at Credit Suisse. Company should see a rebound in hip and knee sales. Management is also likely to buy back more stock. $72 price target.